Skip to main content
SpringerLink
Log in

Warfarin Metabolism and Drug-Drug Interactions

  • Chapter
The New Dimensions of Warfarin Prophylaxis

Abstract

Drug interactions with warfarin vary from useful to disastrous. The pharmacologic combination of warfarin and a platelet inhibitor can be clinically efficacious. Contrarily, the increasing number of drugs that interact with warfarin can potentiate its anticoagulant effect and cause life-threatening hemorrhagic events. To avoid the futility of memorizing long lists of these drugs, guidelines will be presented for the prescribing physician. These concepts are understood best after the metabolism of warfarin in man is reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. P. J. Kearns, and R. A. O’Reilly, Bioavailability of warfarin in a patient with short bowel syndrome, J. Paren. Ent. Nutr. 10:10.0 (1986).

    Google Scholar 

  2. R. A. O’Reilly, Drug-induced vitamin K deficiency, resistance and drug interactions, in: “Prothrombin and Other Vitamin K Proteins,” Vol. II. W. H. Seegers and D. A. Walz, ed., CRC Press, Boca Raton (1986).

    Google Scholar 

  3. R. A. O’Reilly and P. A. Aggeler, Determinants of the response to oral anticoagulant drugs in man, Pharmacol. Rev. 22:35 (1970).

    PubMed  Google Scholar 

  4. R. J. Lewis, W. F. Trager, K. K. Chan, A. Breckenridge, M. Orme, M. Roland, and W. Schary, Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone, J. Clin. Invest. 53:1607 (1974).

    Article  PubMed  CAS  Google Scholar 

  5. R. A. O’Reilly, Anticoagulant, antithrombotic, and thrombolytic drugs, in: “Goodman and Gilman’s The Pharmacological Basis of Therapeutics,” A. G. Gilman, L. S. Goodman, T. W. Rall, and F. Murad, eds., Chap. 58, Macmillan, New York (1985).

    Google Scholar 

  6. B. M. Rifkind, Lipid Research Clinics Program, J.A.M.A. 252:2547 (1984).

    Article  Google Scholar 

  7. R. A. O’Reilly, Drug interactions involving oral anticoagulants, Cardiovasc. Cl. 6:23 (1974).

    Google Scholar 

  8. D. B. Hunninghake and D. M. Hibbard, Influence of time intervals for cholestyramine dosing on the absorption of hydrochlorothiazide, Clin. Pharmacol Ther. 39:329 (1986).

    Article  PubMed  CAS  Google Scholar 

  9. J. M. Van den Broek, H. C. Ten Wolde-Kraamwinkel, C. H. Kleinbloesem and D. D. Breimer, Effect of rifampicin treatment on in vitro drug-metabolizing activities in the pig, Biochem. Pharmacol. 33:325 (1984).

    Article  PubMed  Google Scholar 

  10. R. A. O’Reilly, Interaction of chronic, daily warfarin therapy and rifampin, Ann. Int. Med. 83:506 (1975).

    Article  PubMed  Google Scholar 

  11. R. A. O’Reilly, Lack of effect of mealtime wine on the hypoprothrombinemia or oral anticoagulants, Am. J. Med. Sci. 277:189 (1979).

    Article  PubMed  Google Scholar 

  12. R. A. O’Reilly, Lack of effect of fortified wine ingested during fasting and anticoagulant therapy, Arch. Int. Med. 141:458 (1981).

    Article  Google Scholar 

  13. R. A. O’Reilly, M. A. Sahud, and P. M. Aggeler, Impact of aspirin and chlorthalidone on the pharmacodynamics of oral anticoagulant drugs in man, Ann N. Y. Acad. Sci. 179:173 (1971).

    Article  PubMed  Google Scholar 

  14. R. A. O’Reilly, Interaction of spironolactone and racemic warfarin in man, Clin. Pharmacol. Ther. 27:198 (1980).

    Article  PubMed  Google Scholar 

  15. P. G. Frick, G. Riedler, and H. Brogli, Dose response and minimal daily requirement for vitamin K in man, J. Appl. Physiol. 23:387 (1967).

    PubMed  CAS  Google Scholar 

  16. L. Uotila, J. W. Suttie, Inhibition of vitamin K-dependent carboxylase in vitro by cefamandole and its structured analogs, J. Infect. Dis. 148:571 (1983).

    Article  PubMed  CAS  Google Scholar 

  17. R. A. O’Reilly and D. A. Rytand, “Resistance” to warfarin due to unrecognized vitamin K supplementation, N. Engl. J. Med. 303:160 (1980).

    PubMed  Google Scholar 

  18. S. J. Kempin, Warfarin resistance caused by broccoli, N. Engl. J. Med. 308:1229 (1983).

    Article  PubMed  CAS  Google Scholar 

  19. R. A. O’Reilly, M. A. Sahud, and A. J. Robinson, Studies on the interaction of warfarin and Clofibrate in man, Throm. Diath. Haemorrh. 27:309 (1972).

    Google Scholar 

  20. R. A. O’Reilly, Editorial: complications of anticoagulant therapy, West. J. Med. 132:453 (1980).

    PubMed  Google Scholar 

  21. T. W. Meade, Safety of oral anticoagulation, Lancet 1:1387 (1986).

    Article  PubMed  CAS  Google Scholar 

  22. R. Hull, J. Hirsh, R. Jay, C. Carter, C. England, M. Gent, A. G. G. Turpie, D. McLoughlin, P. Dodd, M. Thomas, G. Raskob, and P. Ockelford, Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis, N. Engl.J. Med. 307:1676 (1982).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine, Santa Clara Valley Medical Center, Stanford University School of Medicine, University of California, San Francisco, San Jose, California, USA

    Robert A. O’Reilly

Authors
  1. Robert A. O’Reilly
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. New York University School of Medicine, New York, New York, USA

    Stanford Wessler

  2. Cornell University Medical College, New York, New York, USA

    Carl G. Becker

  3. Mt. Sinai School of Medicine of the City University of New York, New York, New York, USA

    Yale Nemerson

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer Science+Business Media New York

About this chapter

Cite this chapter

O’Reilly, R.A. (1987). Warfarin Metabolism and Drug-Drug Interactions. In: Wessler, S., Becker, C.G., Nemerson, Y. (eds) The New Dimensions of Warfarin Prophylaxis. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-5985-3_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-5985-3_18

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4757-5987-7

  • Online ISBN: 978-1-4757-5985-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation